Arbutus Biopharma (ABUS) Non-Current Assets (2010 - 2026)
Arbutus Biopharma (ABUS) posted Non-Current Assets of $153000.0 for Q1 2026, down 5.56% sequentially from $162000.0 in Q4 2025, and down 24.26% YoY from $202000.0 in Q1 2025.
Arbutus Biopharma (ABUS) Non-Current Assets (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Non-Current Assets for 17 years, with the latest figure at $153000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 24.26% year-over-year to $153000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $731000.0 (down 96.96% YoY) and the FY2025 annual result came in at $162000.0, down 96.31% from the prior year.
- Non-Current Assets slipped to $153000.0 in Q1 2026 per ABUS's latest filing, from $162000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $64.2 million in Q1 2022 and troughed at $148000.0 in Q2 2025.
- A 5-year average of $20.8 million and a median of $12.4 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 621.19% in 2022, then sank 98.75% in 2025.
- Over 5 years, Non-Current Assets stood at $44.3 million in 2022, then tumbled by 72.06% to $12.4 million in 2023, then slumped by 64.51% to $4.4 million in 2024, then tumbled by 96.31% to $162000.0 in 2025, then dropped by 5.56% to $153000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $153000.0, $162000.0, and $268000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 142,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142,000.00 |
| Mar 31, 2026 | 153,000.00 |
| Dec 31, 2025 | 162,000.00 |
| Sep 30, 2025 | 268,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 4.39 Mn |
| Sep 30, 2024 | 7.66 Mn |
| Jun 30, 2024 | 11.82 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 12.37 Mn |
| Sep 30, 2023 | 17.03 Mn |
| Jun 30, 2023 | 18.02 Mn |
| Mar 31, 2023 | 38.37 Mn |
| Dec 31, 2022 | 44.28 Mn |
| Sep 30, 2022 | 62.67 Mn |
| Jun 30, 2022 | 58.05 Mn |
| Mar 31, 2022 | 64.18 Mn |
| Dec 31, 2021 | 43.82 Mn |
| Sep 30, 2021 | 39.06 Mn |